会议介绍
PEGS China已经跨过四个年头，如今已成为生物医药行业研究员要参加的活动之一。PEGS China将在2017年3月28日至30日再次在上海召开，邀请具有影响力的国际和国内演讲嘉宾来展示未出版的数据和新案例研究，来呈现最新的国际发展项目、行业趋势以及中国生物技术行业的未来发展潜力。
会议 1: Protein & Antibody Engineering 蛋白质与抗体工程
在中国举办聚焦于蛋白质工学与抗体工学的会议
近年中国在全球生物医药产业中崛起，其真正价值不仅在监管机构的指导体制及审核路径上、在新生物学治疗药物研发成果上也面临考验。2017年3月28日至30日在中国上海举办的第4届PEGS Summit，制药企业高层与意见领袖齐聚一堂，针对创新的创药议程、尖端技术成果、解决问题的最佳实例与学习等主题展开热烈的讨论。
2017年焦点：免疫疗法作为癌症治疗创新方法的重要性日益升高，学会也新增了「癌症免疫」相关分组讨论会。本次会议不仅限于中国，将介绍全球制药公司开发免疫疗法相关产品的生产线与计画发展状况。
Preliminary Agenda
蛋白质与抗体工程
本单元以蛋白质及抗体工程为主题，研究机关与药厂研究人员将分享蛋白质及抗体分子的设计、新药发现、工程研究成果，并讨论克服开发过程中所遇到各类课题的创新策略。
暂定议程
联合主题演讲
Engineering Single-Domain Antibodies for Cancer Therapy
Mitchell Ho, Ph.D., Chief, Antibody Therapy & Senior Investigator, National Institutes of Health
DISPLAY LIBRARIES
A Novel Platform for Human Antibody Discovery Using Yeast Display Antibody Library
Aichi Zhao, Ph.D., President, R&D, OriMabs, Ltd.
Recombinant Antibody Display Libraries - Design, Construction and Selection
Eunice Zhou, Ph.D., Associate Adjunct Professor, Anesthesia, UC San Francisco
蛋白质及抗体产生
Generation of Humanized Antibody Transgenic Animal (Camouse) for Producing Human Antibody
Liangpeng Ge, Ph.D., Director, Institute of Bingengineering, Chongqing Academy of Animal Sciences
New Techniques for in vitro Evolution and Selection of Enzymes
Manfred Konrad, Ph.D., Max-Planck Institute for Biophysical Chemistry, Head, Enzyme Biochemistry Laboratory
蛋白质与标靶工程
Case Study
Engineering G-Protein Coupled Receptors for High Production and Efficient Folding In Synthetic Environments
Frank Bernhard, Ph.D., Lab Manager, Biophysical Chemistry, Goethe University Frankfurt
Computationally-Driven Engineering of an Anti-Tumor Antibody
Chris Bailey-Kellogg, Ph.D., Professor, Computer Science, University of Dartmouth
新生物学治疗药物开发
Engineering Anti-VEGFR2 X Anti-PDGFR-Beta Bispecific Antibodies for the Treatment of Cancer and Ophthalmological Diseases
Zhenping Zhu, Ph.D., Executive Vice President, Global Biologics R&D, Kadmon Corp, LLC.
Nexmab Antibody-Drug Conjugate for the Treatment of Ovarian Cancer
Sunbae Lee, Ph.D., Senior Research Scientist, R&D Center, Alteogen, Inc.
* 活动内容有可能不事先告知作更动及调整。
蛋白质聚集与稳定性
近年，蛋白质聚集、粒子、sub-visible particle相关研究变得越来越重要。聚集形成的机制，以及其发展和配方的影响，已成为许多研究与讨论的主题。在本单元中，除了将分享动力学研究成果以深入理解聚集原因，也聚焦提升稳定性和控制聚集的分析及配方策略。
暂定议程
联合主题演讲
Engineering Single-Domain Antibodies for Cancer Therapy
Mitchell Ho, Ph.D., Chief, Antibody Therapy & Senior Investigator, National Institutes of Health
聚集形成
Determinant Factor for Aggregation and Fragment Formation: Oxidation
Joy Zhou, Ph.D., Principal Scientist, Associate Director, DP MST, Shire
Protein Aggregation during Formulation and Drug Product Manufacturing and Mitigation Strategies
Mark Yang Ph.D., Director, Fill Finish Development, BioPharmaceutical Development, Genzyme
发展性与处方开发的聚集分析
Aggregation Analysis at High and Low Concentrations
Jennifer McManus, Ph.D., Lecturer, Department of Chemistry, National University of Ireland Maynooth
How to Optimize Stability of Drug Substance and Drug Product through Integration of Rapid and Sensitive Analytical Tools with Rational Approach to Developability Assessment and Early Formulation Development
Danny Chou, Ph.D., President, Compassion BioSolutions, LLC.
Heavy Chain of Mouse IgM Can Be Cleaved Between CH1 and CH2 Domains by a Protease Present in Serum
Tomasz Klaus, MSc, Research Assistant, Malopolska Centre of Biotechnology, Jagiellonian University, Krakow
稳定性与传输装置课题
Impact of Product Heterogeneity on Product Biological Activity and Stability in the Context of Bio-therapeutics
Ravish Patel, Ph.D., Scientist, Bioanalytical (Biologics), Analytical Development Lab, EPR Centre for Cancer Research and Bioinformatics Pvt. Ltd. (A Vitane Group of Companies)
Modified Phosphate Buffered Saline (PBS) as a Viable Vehicle for Biotherapeutic Drugs
Tatyana Mezhebovsky, Ph.D., Principal Scientist, BioFormulations, Sanofi US
* 活动内容有可能不事先告知作更动及调整。
癌症免疫
本单元以癌症免疫为主题，本领域意见领袖及先驱研究人员，将讨论中国目前研究现况，并聚焦推动新分子至临床研究阶段的创新方法与尖端技术。
暂定议程
联合主题演讲
Multimodal Cancer Therapy - Dynamic Process-Based Immuno-oncology
Bertil Lindmark, M.D., Ph.D., CMO, ASLAN Pharmaceuticals
Rational Combination of Immune-Oncology Agents
Lei Zheng, Ph.D., Associate Professor, Oncology and Surgery, Gastrointestinal Cancer Program, Tumor Immunology Program, Johns Hopkins University School of Medicine
联合会议－T细胞工程分析策略
Versatile Strategy for Controlling the Specificity and Activity of Engineered T Cells
Chan Hyuk Kim, Ph.D., Assistant Professor, Biological Sciences, KAIST
Applying a High Content Imaging Assay Platform to Elucidate the Mechanism of Actions of Cancer Immunotherapy
Ming Lei, Senior Research Investigator II, Lead Discovery and Optimization, Bristol-Myers Squibb Company
中国癌症领域PIPELINE与研究成果最新情报
Beyond PD-1: Challenge and Opportunity in Immuno-Oncology
Hongtao Lu, Ph.D., Executive Vice President & CSO, Discovery, Zai Laboratory
Improving the Efficacy of Immuno-Checkpoint Inhibitor through Target Mediated Antibody Recycling and Combination Interventions
Xueming Qian, Ph.D., Chairman & CEO, MabSpace Biosciences
Screening PD1 inhibitors and Beyond
Bo Chen, Ph.D., CEO, Shanghai Junshi
Updates on Alphamab's Molecules in the Clinic Targeting PDl-1 and CTLA-4
Ting Xu, Ph.D., CEO & President, Alphamab
The Design and Development of Novel Biologics for Cancer Immunotherapies
Jinming Gu, Ph.D., Executive Director, Biologics Discovery, Shanghai Hengrui Pharmaceutical Co., Ltd.
Novel Bispecific Antibody Technology for Cancer Immunotherapeutics
Chengbin Wu, Ph.D., CEO, Epimab
Amgen's BiTE Bispecific T-Cell Engaging Antibody for Immunotherapy
MingQiang Zhang, Ph.D., Head, R&D, Amgen Asia
Agonist Antibody in Immune-Oncology, in Mono- and Combination Therapies (tentative)
Peter Luo, Ph.D., CEO & Co-Founder, Adagene
* 活动内容有可能不事先告知作更动及调整。
生物学治疗药物表徵分析
本单元以生物学治疗药表徵分析为主题，将重点摆在提供各种能加速技术创新的方法，将透过具独创性的策略及最新技术研究发表，分享有助开发具优异特徵新生物学治疗药物的想法、专业知识、解决方案。
暂定议程
联合主题演讲
Multimodal Cancer Therapy - Dynamic Process-Based Immuno-oncology
Bertil Lindmark, M.D., Ph.D., CMO, ASLAN Pharmaceuticals
Rational Combination of Immune-Oncology Agents
Lei Zheng, Ph.D., Assistant Professor, Oncology and Gastrointestinal Cancer, Johns Hopkins University
联合会议－T细胞工程的分析策略
Versatile Strategy for Controlling the Specificity and Activity of Engineered T Cells
Chan Hyuk Kim, Ph.D., Assistant Professor, Biological Sciences, KAIST
Applying a High Content Imaging Assay Platform to Elucidate the Mechanism of Actions of Cancer Immunotherapy
Ming Lei, Senior Research Investigator II, Lead Discovery and Optimization, Bristol-Myers Squibb Company
优化与发展性
Integrated Technology Solutions to Support Biologics Hit to Lead and Beyond
Han Li, Ph.D., Principal Scientist, Leads Discovery & Optimization, Bristol-Myers Squibb Company
Mutational Approaches to Improve the Biophysical Properties of Single Domain Antibodies
Jamshid Tanha, Ph.D., Senior Research Officer, Human Health Therapeutics Portfolio, National Research Council Canada
新BIOSIMILAR产品结构面与功能面表徵分析
Effects of Glycosylation on Biological Activities of Therapeutic Antibodies
Shan Chung, Ph.D., Senior Scientist and Group Leader, Bioanalytical Sciences, Genentech
Oxidative Post-Translational Modification - Impact on Stability and Formulation of Protein Therapeutics
Christian Schoeneich, Ph.D., Professor and Chair, Pharmaceutical Chemistry, University of Kansas Lawrence
Higher Order Structure Analysis of Antibodies by Hydrogen/Deuterium Exchange Mass Spectrometry
Susumu Uchiyama, Ph.D., Associate Professor, Graduate School of Engineering, Osaka University
Physicochemical and Functional Characterization of Biosimilar Bevacizumab
Ravish Patel, Ph.D., Scientist, Bioanalytical (Biologics), Analytical Development Lab, EPR Centre for Cancer Research and Bioinformatics Pvt. Ltd., India
* 活动内容有可能不事先告知作更动及调整。
标准套餐 (包括两个会议和SEMINAR)
Advance Registration Rates until February 17 CNY6890
Standard Registration Rates after February 17 and onsite CNY7420
基础套餐 (包括一个会议或者SEMINAR )
Advance Registration Rates until February 17 CNY5300
Standard Registration Rates after February 17 and onsite CNY5830
以上价格均为含税价, 提供正式发票.